الفهرس 
Hepatitis C Virus & IronOnly 14 pages are availabe for public view
 |  | from | 146 |  |  |
| | | from | 146 | | |
Abstract
Background: HCV infection which affects nearly 3% of the human population, is a major cause of liver disease worldwide. The spectrum of this disease is quite variable, ranging from acute hepatitis to cirrhosis and hepatocellular carcinoma. It remains a major indication for liver transplantation in developed countries. Elevated iron parameters and mild iron overload are common in the liver of patients with chronic hepatitis C. Aim of the Work: The aim of this work is to evaluate the effect of Direct Acting Antiviral Drugs for chronic HCV infection on Iron profile & the impact of Iron profile in response to treatment. Patients and methods: This study was conducted in EL Nasr Hepatology clinic and El Demerdash virology clinic. The study included 90 patients with chronic HCV infection who were candidate for treatment with new direct acting antiviral drugs according to recent guidelines of treatment of chronic HCV infection. A prospective study was done by sampling for Iron profile (serum Iron, serum Ferritin & TIBC) & PCR before receiving the treatment & one month after completion of treatment course. Results: after treatment there was a non significant decrease in serum Iron in group I (78.17±25.20 µg/dl) & a non significant increase in group II(81.60±30.00 µg/dl), while in group III there was a significant increase in serum iron (79.73±38.31 µg/dl). For ferritin levels, group I showed a highly significant decrease (125.10±67.86 ng/mL), while there was a non significant increase in group II (180.07±116.94 ng/mL). On the other hand, group III showed a non significant decrease in serum ferritin (96.47±52.04 ng/mL). For TIBC, there was a highly significant decrease in group I, II & III (294.50±47.75 µg/dL, 337.67±40.08 µg/dL &300.60±51.47 µg/dL), respectively.. Conclusion: We can conclude that TIBC was decreased in HCV patients received Sofosbuvir and Daclatasvir ± Ribavirin & Ombitasvir / Paritaprevir / Ritonavir and Ribavirin. Serum ferritin decreased in HCV patients received Sofosbuvir and Daclatasvir, while no difference in patients received Sofosbuvir and Daclatasvir + ribavirin & Ombitasvir / Paritaprevir / Ritonavir and Ribavirin. Serum Iron increased in HCV patients received Ombitasvir / Paritaprevir / Ritonavir and Ribavirin, while no difference in patients received Sofosbuvir and Daclatasvir ± Ribavirin. Recommendations: Increasing the number of study population is recommended for better assay and evaluation. Comparing iron profile results between treatment responders and non responders in each regimen for HCV treatment is recommended for evaluation of the impact of iron profile in treatment response.